Lenalidomide
Medicare prescription drug cost, prescriptions and prescribers, 2024
$2.64B
Medicare cost, 2024
$2.64B
Medicare cost, 2024
Medicare drug plans spent $2.6 billion on Lenalidomide in 2024, for 197,995 prescriptions and refills filled by 30,339 patients. It ranks 17th among all drugs by Medicare drug plan spending. Spending rose 57% from 2023 to 2024. It was first approved in 2021.
Medicare cost, 2024
$2.64B
+57.1% from 2023
Prescriptions
198K
$13,334.05 per claim
Patients
30K
10,560 prescribers
Total spending, 2024
$2.64B
$87,001.87 per patient
Questions and answers
How much does Medicare spend on Lenalidomide?
Medicare prescription drug plans paid $2.64B for Lenalidomide in 2024, for 197,995 prescriptions and refills to 30,339 patients (up 57.1% from 2023). The average cost per claim was $13,334.05.
Which state spends the most on Lenalidomide?
California had the highest Medicare cost for Lenalidomide in 2024: $318.9M for 25,305 claims, followed by New York ($226.8M).
Who prescribes Lenalidomide the most?
Emerentia A Agyemang, nurse practitioner in Boston, MA, had the highest Medicare cost for Lenalidomide in 2024: 537 claims costing $6.5M.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Lenalidomide was $2.64B in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Lenalidomide, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Emerentia A Agyemang Boston, MA | Nurse Practitioner | 537 | 85 | $6.5M |
| Jennifer E Miller Rochester, NY | Nurse Practitioner | 366 | 77 | $5.7M |
| Gina B Fries Rochester, NY | Physician Assistant | 361 | 73 | $5.2M |
| Ami P Ndiaye Charlotte, NC | Nurse Practitioner | 355 | 88 | $5.0M |
| Rachid C Baz Tampa, FL | Hematology-Oncology | 340 | 71 | $4.8M |
| Ian T Lund Buffalo, NY | Physician Assistant | 285 | 94 | $4.7M |
| Andrew P Dalovisio Baton Rouge, LA | Hematology-Oncology | 314 | 60 | $4.6M |
| Katie Jones New York, NY | Nurse Practitioner | 312 | 80 | $4.5M |
| Larry D Anderson Jr. Dallas, TX | Hematopoietic Cell Transplantation and Cellular Therapy | 360 | 49 | $4.4M |
| Ferdinand D Dayalo South El Monte, CA | Nurse Practitioner | 366 | 51 | $4.4M |
| Michael M Green Baltimore, MD | Hematology-Oncology | 359 | 46 | $4.3M |
| Sascha A Tuchman Durham, NC | Hematopoietic Cell Transplantation and Cellular Therapy | 279 | 39 | $4.2M |
| Kristina M Slemmer Buffalo, NY | Physician Assistant | 251 | 88 | $4.2M |
| Jordan D Robinson Charlotte, NC | Physician Assistant | 291 | 80 | $4.1M |
| Kenneth S Poon San Leandro, CA | Hematology-Oncology | 341 | 35 | $3.7M |
| Kevin Brigle Richmond, VA | Nurse Practitioner | 261 | 37 | $3.5M |
| Hailey Battaglia Knight Chicago, IL | Physician Assistant | 217 | 93 | $3.5M |
| Jill N Burke Boston, MA | Nurse Practitioner | 252 | 32 | $3.4M |
| Brandon J Blue Tampa, FL | Hematology-Oncology | 240 | 50 | $3.4M |
| Craig C Hofmeister Atlanta, GA | Hematology | 240 | 38 | $3.3M |
| Susan Y Kao Berkeley, CA | Internal Medicine | 245 | 28 | $3.2M |
| Sendhilnathan Ramalingam Durham, NC | Hematology-Oncology | 244 | 39 | $3.2M |
| Al-Ola A Abdallah Tulsa, OK | Hematology | 234 | 50 | $3.2M |
| Nisha S Joseph Atlanta, GA | Medical Oncology | 223 | 29 | $3.1M |
| Michael Toole Fort Wayne, IN | Hematology-Oncology | 211 | 32 | $3.1M |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 5,315 | 32,301 | 9,847 | $448.2M |
| 2023 | 8,741 | 121,722 | 20,385 | $1.68B |
| 2024 | 10,560 | 197,995 | 30,339 | $2.64B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Teva Pharm | 66,919 | $876.3M |
| Dr.Reddy'S Lab | 37,825 | $503.6M |
| Alvogen Inc | 25,519 | $354.5M |
| Apotex Corp | 21,196 | $289.9M |
| Cipla USA, Inc. | 9,628 | $129.5M |
| Zydus Pharmaceu | 8,247 | $115.3M |
| Sun Pharmaceuti | 8,414 | $108.8M |
| Mylan | 9,027 | $107.1M |
| Camber Pharmace | 6,536 | $90.8M |
| Aurobindo Pharm | 4,756 | $64.9M |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 180
- RxNorm concept IDs
- 1242231, 1428947, 602910, 602912, 643712
- Application numbers
- ANDA201452, ANDA209348, ANDA210154, ANDA210435, ANDA210480
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 425,920 side-effect reports named lenalidomide (reports from 2003 on). 271,850 of them (63.8%) were serious, 54,138 named a death and 110,525 named a hospital stay. The reactions named most often were diarrhoea, fatigue and death. 143,660 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
425,920
23,903 in 2025 (-21.5% from 2024)
Serious
63.8%
271,850 reports
Deaths named
54,138
12.7% of reports
Hospital stays
110,525
25.9% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Lenalidomide?
425,920 reports from 2003 through September 2026 named lenalidomide. 271,850 of them (63.8%) were serious, 54,138 named a death and 110,525 named a hospital stay.
What are the most reported side effects of Lenalidomide?
31,968 reports named diarrhoea, the reaction named most often, followed by fatigue (27,107) and death (26,874). In the last 5 years the reaction named most often was off label use (17,687 reports). A report can name several reactions.
How many side-effect reports named Lenalidomide in 2025?
23,903 reports were received in 2025 (-21.5% from 2024). 2026 so far: 16,693 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Lenalidomide caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Lenalidomide caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with lenalidomide: Revlimid
- Makers on the stock market:
BMY·BMY drug pipeline - Drug approvals (18 approvals on file for lenalidomide) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (lenalidomide) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.